RxDoctor Payments Data

Donald Douglas, MD

Internal Medicine · New Boston, TXNPI 1851385793

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $325 of the $385 with a category attached, or 84.4%. 8 manufacturers reported payments, led by Johnson & Johnson at 32.8% of the total. Reporting peaked in 2019 at $195 and has fallen 70.5% since, to $57 in 2024.

$385in general payments, 2019–2025

Across 24 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$126
  • AbbVie$117
  • Sanofi-aventis U.S. LLC$48
  • Otsuka America Pharmaceutical, Inc.$26
  • Jazz Pharmaceuticals Inc.$24
  • GE HealthCare$16
  • plus $28 from 2 others
$12,790in research payments, 2019–2025

Across 4 payments — averaging $3197.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$13K

What the payments were for

  • Food & beverage$32584%
  • Education$6016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$385 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$255,495
Medicare patients
407
Services billed
6,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$44,530
MounjaroTirzepatide32$31,897
OzempicSemaglutide17$17,630
MyrbetriqMirabegron17$15,027
JanuviaSitagliptin Phosphate14$13,250
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,862
Breo ElliptaFluticasone/Vilanterol15$8,833
XareltoRivaroxaban13$5,567
TradjentaLinagliptin17$5,456
JardianceEmpagliflozin13$3,963
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen216$3,538
Gabapentin168$2,724
Levothyroxine Sodium248$2,448
Duloxetine Hcl62$1,936
Donepezil Hcl50$1,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$14$31,89732 claims
MerckJanuvia$14$13,25014 claims
Johnson & JohnsonXarelto$126$5,56713 claims
Sanofi-aventis U.S. LLCLantus$48$1,54116 claims
AbbVieSynthroid$117$1,12911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in New Boston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →